Evidence map›Paper›PMID 37630785›Full record

Observational studyNutrients2023

Mid-Term Evolution of the Serum Acylcarnitine Profile in Critically Ill Survivors: A Metabolic Insight into Survivorship.

Anne-Françoise Rousseau, Arsène Ngongan, Camille Colson, Pauline Minguet, Sarah Neis-Gilson, Etienne Cavalier, Grégory Minguet, Benoit Misset, François Boemer

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Anne-Françoise RousseauIntensive Care Department and Burn Centre, University Hospital of Liège, University of Liège, 4000 Liège, Belgium.ORCID 0000-0002-4157-6570
Arsène NgonganIntensive Care Department and Burn Centre, University Hospital of Liège, University of Liège, 4000 Liège, Belgium.
Camille ColsonIntensive Care Department and Burn Centre, University Hospital of Liège, University of Liège, 4000 Liège, Belgium.
Pauline MinguetIntensive Care Department and Burn Centre, University Hospital of Liège, University of Liège, 4000 Liège, Belgium.
Sarah Neis-GilsonIntensive Care Department and Burn Centre, University Hospital of Liège, University of Liège, 4000 Liège, Belgium.
Etienne CavalierClinical Chemistry Department, University Hospital, University of Liège, 4000 Liège, Belgium.
Grégory MinguetGIGA-Research, GIGA-I3 Thematic Unit, Inflammation and Enhanced Rehabilitation Laboratory (Intensive Care), University of Liège, 4000 Liège, Belgium.
Benoit MissetIntensive Care Department and Burn Centre, University Hospital of Liège, University of Liège, 4000 Liège, Belgium.
François BoemerBiochemical Genetics Lab, Department of Human Genetics, University Hospital, University of Liège, 4000 Liège, Belgium.ORCID 0000-0003-4470-9524
University of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is unknown if the abnormal acylcarnitine (AC) profile observed early after discharge of a prolonged stay in an intensive care unit (ICU) would persist over time. This prospective observational study aimed to describe the mid-term AC profile evolution in survivors of a prolonged ICU stay (≥7 days). Adults enrolled in our post-ICU follow-up program and who attended the consultation 3 months (M3) after discharge were included. Serum AC concentrations were assessed within 7 days following ICU discharge (T0) and at M3. A total of 64 survivors were analyzed after an ICU stay of 15 (9-24) days. Free carnitine (C0) concentration decreased from 45.89 (35.80-127.5) to 28.73 (20.31-38.93) µmol/L (

Indexed as

Critical IllnessSurvivorshipAdultCarnitineHumansSurvivorsacylcarnitineCarnitinecarnitinecatabolismcritical illnessmitochondrial dysfunctionmusclesurvivors

Identifiers

PMID37630785
PMCPMC10458357
OpenAlexW4385949300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.